Grant: Operating Grant: Clinical Trials Projects - Indirect Costs

REMAP-CAP, or Randomized Embedded Multifactorial Adaptive Platform trial of Community Acquired Pneumonia, is a world-leading platform of randomized clinical trials designed to optimize the care of the sickest infected patients. Across all causes of community-acquired pneumonia, which remains one of the leading causes of mortality across the world, we aim to incrementally improve clinical outcomes through robust evidence generation via randomization. This proposal is for influenza-specific recruitment onto the platform. The primary outcome will be 90-day mortality. We have documented feasibility through a number of publications across the platform. Our trial has won international awards for clinical trial design from a number of statistical societies. We will continue to improve care for the sickest patients around the world, led by Canadians.